AR121850A2 - LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION - Google Patents

LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION

Info

Publication number
AR121850A2
AR121850A2 ARP210100996A ARP210100996A AR121850A2 AR 121850 A2 AR121850 A2 AR 121850A2 AR P210100996 A ARP210100996 A AR P210100996A AR P210100996 A ARP210100996 A AR P210100996A AR 121850 A2 AR121850 A2 AR 121850A2
Authority
AR
Argentina
Prior art keywords
lpa
agent
rnai
rna interference
inhibiting
Prior art date
Application number
ARP210100996A
Other languages
Spanish (es)
Inventor
Stacey Melquist
Steven Kanner
David B Rozema
David L Lewis
Lauren J Almeida
Darren H Wakefield
Vladimir S Trubetskoy
Tao Pei
Zhen Li
Aaron Almeida
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of AR121850A2 publication Critical patent/AR121850A2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agente de interferencia de ARN LPA (ARNi) que comprende una cadena sentido y una cadena antisentido donde dicha cadena antisentido comprende la secuencia de nucleótidos de a) nucleótidos 2 - 19 de cualquiera de las SEQ ID Nº 1 - 108 o b) cualquiera de las cadenas antisentido de la Tabla 1 o Tabla 2ᵃ, uso de dicho agente; y método para inhibir la expresión de LPA en una célula, tejido, o sujeto.LPA RNA interference agent (RNAi) comprising a sense strand and an antisense strand wherein said antisense strand comprises the nucleotide sequence of a) nucleotides 2-19 of any of SEQ ID NOs 1-108 or b) any of the strands antisense from Table 1 or Table 2ᵃ, use of said agent; and method of inhibiting expression of LPA in a cell, tissue, or subject.

ARP210100996A 2015-10-01 2021-04-15 LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION AR121850A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
AR121850A2 true AR121850A2 (en) 2022-07-13

Family

ID=60923936

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160103006A AR106227A1 (en) 2015-10-01 2016-09-30 COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)
ARP210100996A AR121850A2 (en) 2015-10-01 2021-04-15 LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP160103006A AR106227A1 (en) 2015-10-01 2016-09-30 COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)

Country Status (1)

Country Link
AR (2) AR106227A1 (en)

Also Published As

Publication number Publication date
AR106227A1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
WO2018041973A9 (en) Chemically modified single-stranded rna-editing oligonucleotides
PE20210921A1 (en) ARNI AGENTS AS INHIBITORS OF SERPINE 1 TRANSCRIPTION AND COMPOSITIONS THAT INCLUDE THEM
CO2017007335A2 (en) Suppression of the arni-induced huntingtin gene
EA201991369A1 (en) MODIFIED RNA GUIDES
EA201892467A1 (en) Oligonucleotide Analogues Aimed at Human LMna
BR112016029178A2 (en) compositions and methods for the expression of crispr guide rs using the h1 promoter
BR112017006469A2 (en) compositions and methods for inhibiting expression of the gene hao1 (hydroxy acid oxidase 1 (glycolate oxidase))
PE20191351A1 (en) AAV TREATMENT OF HUNTINGTON'S DISEASE
PE20211393A1 (en) ARNi COMPOSITIONS AGAINST COMPLEMENT COMPONENT C5 AND METHODS FOR ITS USE
AR102777A1 (en) COMPOSITIONS OF ARNi AGAINST TMPRSS6 AND METHODS FOR USE
CO2021018034A2 (en) Modified gapmer oligonucleotides and methods of use
WO2016164896A3 (en) Modulation of smn expression
AR100946A1 (en) COMPOSITIONS AND METHODS TO REGULATE GENE EXPRESSION THROUGH RNA INTERFERENCE
PH12020500527A1 (en) Rna molecules
MX2017008587A (en) NATURALLY OCCURING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME.
IL288490A (en) Antisense rna editing oligonucleotides comprising cytidine analogs
MX2016014760A (en) Niacinamide for inducing generation of antimicrobial peptides.
BR112016002524A2 (en) molecular targets for the prevention and / or treatment of fibrosis, hypertrophic scars and keloids
EP3246406A4 (en) Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
CL2021002842A1 (en) Inhibitory double-stranded nucleic acid molecules with shortened sense strands
IT201700036472A1 (en) ARMREST AXIAL TRAVELING DEVICE, IN PARTICULAR FOR OFFICE CHAIRS
ZA201806273B (en) Compositions and methods for treatment of type vii collagen deficiencies
WO2015113004A3 (en) Oligonucleotides and methods for treatment of cardiomyopathy using rna interference
CL2017002726A1 (en) Cosmetic method and therapeutic use for fat reduction
BR112018070249A2 (en) tissue specific expression modified u6 promoter system